Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh

Vaccine

Volumn 32, Issue 9, 2014, Pages 1055-1060

  Bhuiyan, Taufiqur R ^a   Choudhury, Feroza K ^a   Khanam, Farhana ^a   Saha, Amit ^a   Sayeed, Md Abu ^a   Salma, Umme ^a   Lundgren, Anna ^b   Sack, David A ^c   Svennerholm, Ann Mari ^b   Qadri, Firdausi ^a  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antibodies; Children; Mucosal; Oral; T cells; Typhoid vaccine

Indexed keywords

ANTIBODIES; CHILDREN; MUCOSAL; ORAL; T CELLS; TYPHOID VACCINE;

ADMINISTRATION, ORAL; ALBENDAZOLE; ANTHELMINTICS; ANTIBODIES, BACTERIAL; BANGLADESH; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METRONIDAZOLE; PILOT PROJECTS; POLYSACCHARIDES, BACTERIAL; T-LYMPHOCYTES; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES;

EID: 84895063983     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.001     Document Type: Article

References (32)

1. Brooks W.A., Hossain A., Goswami D., Nahar K., Alam K., Ahmed N., et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005, 11:326-329.
2. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Org 2004, 82:346-353.
3. Saha S.K., Baqui A.H., Hanif M., Darmstadt G.L., Ruhulamin M., Nagatake T., et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J 2001, 20:521-524.
4. Szu S.C., Robbins J.B., Schneerson R., Lin F.Y. Polysaccharide-based conjugate vaccines for enteric bacterial infections: typhoid fever, non-typhoidal Salmonellosis, and Escherichia coli 0157:H7. New Generation Vaccines 2010, 489. Informa Healthcare USA, Inc., New York, NY. M.M. Levine (Ed.).
5. Khan M.I., Soofi S.B., Ochiai R.L., Habib M.A., Sahito S.M., Nizami S.Q., et al. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine 2012, 30:5389-5395.
6. WHO Typhoid vaccines: WHO position paper. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record/Health Section of the Secretariat of the League of Nations 2008, 83:49-59. WHO.
7. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344:1263-1269.
8. Simon R., Levine M.M. Glycoconjugate vaccine strategies for protection against invasive Salmonella infections. Hum Vaccin Immunother 2012, 8:494-498.
9. Thiem V.D., Lin F.Y., Canh do G., Son N.H., Anh D.D., Mao N.D., et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011, 18:730-735.
10. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999, 17(Suppl 2):S22-S27.
11. Cryz S.J., Vanprapar N., Thisyakorn U., Olanratmanee T., Losonsky G., Levine M.M., et al. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun 1993, 61:1149-1151.
12. Sack D.A.Q.F., Svennerholm A.-M. Determinants of responses to oral vaccines in developing countries. Ann Nestlé (Engl) 2008, 66:71-79.
13. Haque R., Mondal D., Karim A., Molla I.H., Rahim A., Faruque A.S., et al. Prospective case-control study of the association between common enteric protozoal parasites and diarrhea in Bangladesh. Clin Infect Dis 2009, 48:1191-1197.
14. Northrop-Clewes C.A., Rousham E.K., Mascie-Taylor C.N., Lunn P.G. Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, growth, and biochemical status. Am J Clin Nutr 2001, 73:53-60.
15. Thomas T.A., Mondal D., Noor Z., Liu L., Alam M., Haque R., et al. Malnutrition and helminth infection affect performance of an interferon gamma-release assay. Pediatrics 2010, 126:e1522-e1529.
16. Weng M., Huntley D., Huang I.F., Foye-Jackson O., Wang L., Sarkissian A., et al. Alternatively activated macrophages in intestinal helminth infection: effects on concurrent bacterial colitis. J Immunol 2007, 179:4721-4731.
17. Cooper P.J., Chico M., Sandoval C., Espinel I., Guevara A., Levine M.M., et al. Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infect Immunol 2001, 69:1574-1580.
18. Ahren C., Jertborn M., Svennerholm A.M. Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin a responses in blood. Infect Immunol 1998, 66:3311-3316.
19. Qadri F., Ryan E.T., Faruque A.S., Ahmed F., Khan A.I., Islam M.M., et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immunol 2003, 71:4808-4814.
20. Lundgren A., Kaim J., Jertborn M. Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods. Vaccine 2009, 27:4529-4536.
21. Mattsson A., Tinnert A., Hamlet A., Lonroth H., Bolin I., Svennerholm A.M. Specific antibodies in sera and gastric aspirates of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Clin Diagn Lab Immunol 1998, 5:288-293.
22. Achtman M., Morelli G., Schwuchow S. Cell-cell interactions in conjugating Escherichia coli: role of F pili and fate of mating aggregates. J Bacteriol 1978, 135:1053-1061.
23. Bhuiyan T.R., Qadri F., Saha A., Svennerholm A.M. Infection by Helicobacter pylori in Bangladeshi children from birth to two years: relation to blood group, nutritional status, and seasonality. Pediatr Infect Dis J 2009, 28:79-85.
24. Sheikh A., Bhuiyan M.S., Khanam F., Chowdhury F., Saha A., Ahmed D., et al. Salmonella enterica serovar Typhi-specific immunoglobulin A antibody responses in plasma and antibody in lymphocyte supernatant specimens in Bangladeshi patients with suspected typhoid fever. Clin Vaccine Immunol 2009, 16:1587-1594.
25. Sheikh A., Khanam F., Sayeed M.A., Rahman T., Pacek M., Hu Y., et al. Interferon-gamma and proliferation responses to Salmonella enterica Serotype Typhi proteins in patients with S Typhi Bacteremia in Dhaka, Bangladesh. PLoS Negl Trop Dis 2011, 5:e1193.
26. Leach S., Lundgren A., Svennerholm A.M. Different kinetics of circulating antibody-secreting cell responses after primary and booster oral immunizations: a tool for assessing immunological memory. Vaccine 2013, 31:3035-3038.
27. Sztein M.B. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007, 45(Suppl 1):S15-S19.
28. Lundin B.S., Johansson C., Svennerholm A.M. Oral immunization with a Salmonella enterica serovar typhivaccine induces specific circulating mucosa-homing CD4(+) and CD8(+) T cells in humans. Infect Immunol 2002, 70:5622-5627.
29. Eijnden S.V., Goriely S., De Wit D., Goldman M., Willems F. Preferential production of the IL-12(p40)/IL-23(p19) heterodimer by dendritic cells from human newborns. Eur J Immunol 2006, 36:21-26.
30. Siegrist C.A. The challenges of vaccine responses in early life: selected examples. J Comput Pathol 2007, 137(Suppl 1):S4-S9.
31. Levine M.M., Taylor D.N., Ferreccio C. Typhoid vaccines come of age. Pediatr Infect Dis J 1989, 8:374-381.
32. Walsh A.L., Phiri A.J., Graham S.M., Molyneux E.M., Molyneux M.E. Bacteremia in febrile Malawian children: clinical and microbiologic features. Pediatr Infect Dis J 2000, 19:312-318.